Xeris Biopharma Holdings Inc (XERS) Company Profile & Statistics

Xeris Biopharma Holdings Inc
XERS
(Nasdaq - US)
Open
3.08
+0.04 (+1.15%)
in:usd•As of: Nov 22, 2024 15:01 UTC -5
Open
3.04
High
3.10
Low
3.02

About Xeris Biopharma Holdings Inc

CEO

Paul R. Edick

Headquarters

1375 west fulton street, suite 1300

chicago, il 60607, united states

Auditor

Ernst & Young LLP

Employees

377

Share Holders

225

Website

www.xerispharma.com

Industry

biotechnology

Sector

health technology

Company Overview

Xeris Biopharma Holdings is a biopharmaceutical company. It involved in developing and commercializing therapies for patient in endocrinology, neurology and gastroenterology. The company's principal product includes Gvoke(R), a ready-to-use liquid glucagon for the treatment of severe hypoglycemia and Keveyis(R), the first and only FDA-approved therapy for primary periodic paralysis. Xeris Biopharma Holdings, formerly known as Xeris Pharmaceuticals Inc., is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc Statistics

Valuation Measures

Market Capitalization ²	458.42M
Enterprise Value	630.47M
Enterprise Value/EBITDA (ttm)	-21.22
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	N/A
Price to Sales (ttm)	2.40
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	81.75%
Operating Margin (ttm)	-30.43%
Profit Margin (ttm)	-34.27%
Return on Equity (ttm)	-16662.63%
Return on Invested Capital (ttm)	-31.36%
Return on Assets (ttm)	-17.38%

Income Statement

Revenue (ttm)	187.36M
Revenue Per Share (ttm)	1.26
Gross Profit (ttm)	152.44M
EBITDA (ttm)³	-29.70M
Net Income Avi to Common (ttm)	-63.11M
Diluted EPS (ttm)	-0.45

Share Statistics

Beta (5Y Monthly)	2.70
52-Week Change	68.96%
S&P500 52-Week Change	30.89%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	149.08M
Dividend Yield	0.00%
Float ⁴	142.28M
% Held by Insiders	4.56%
% Held by Institutions	42.75%

Balance Sheet

Total Cash (mrq)	69.40M
Total Cash Per Share (mrq)	0.47
Total Debt (mrq)	231.28M
Total Debt/Equity (mrq)	-816.59%
Current Ratio (mrq)	1.79%
Quick Ratio (mrq)	1.29%
Book Value Per Share (mrq)	-0.19

Cash Flow

Operating Cash Flow Per Share (ytd)	-0.26
Free Cash Flow (ytd)	-39.60M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Xeris Biopharma Holdings Inc

Trade With A Regulated Broker